192 related articles for article (PubMed ID: 32501544)
1. Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response.
Carr DF; Turner RM; Pirmohamed M
Br J Clin Pharmacol; 2021 Feb; 87(2):237-255. PubMed ID: 32501544
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy.
Fujita K; Sasaki Y
Curr Drug Metab; 2007 Aug; 8(6):554-62. PubMed ID: 17691917
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
4. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics in cancer therapy: is host genome variability important?
Petros WP; Evans WE
Trends Pharmacol Sci; 2004 Sep; 25(9):457-64. PubMed ID: 15559247
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics: implementing personalized medicine.
Mini E; Nobili S
Clin Cases Miner Bone Metab; 2009 Jan; 6(1):17-24. PubMed ID: 22461093
[TBL] [Abstract][Full Text] [Related]
8. Comparative and veterinary pharmacogenomics.
Mosher CM; Court MH
Handb Exp Pharmacol; 2010; (199):49-77. PubMed ID: 20204583
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenomics: the quest for individualized therapy].
López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
[TBL] [Abstract][Full Text] [Related]
10. Methodological and statistical issues in pharmacogenomics.
Peters BJ; Rodin AS; de Boer A; Maitland-van der Zee AH
J Pharm Pharmacol; 2010 Feb; 62(2):161-6. PubMed ID: 20487194
[TBL] [Abstract][Full Text] [Related]
11. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
Chan CWH; Law BMH; So WKW; Chow KM; Waye MMY
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1395-1404. PubMed ID: 32270286
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
14. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
O'Donnell PH; Ratain MJ
Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics: has the time come for pharmacists to embrace and implement the science?
Beier MT; Panchapagesan M; Carman LE
Consult Pharm; 2013 Nov; 28(11):696-711. PubMed ID: 24217190
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms.
Reis SS; Carvalho AS; Fernandes R
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31284530
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics: historical perspective and current status.
Charlab R; Zhang L
Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
[TBL] [Abstract][Full Text] [Related]
19. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy.
Evans WE
Ther Drug Monit; 2004 Apr; 26(2):186-91. PubMed ID: 15228163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
